文献速递关节外科

寻找初次全髋关节置换术中口服氨甲环酸的最佳方案:一项随机对照试验

Finding the Optimal Regimen for Oral Tranexamic Acid Administration in Primary Total Hip Arthroplasty: A Randomized Controlled Trial.
PubMed 文献 · J Bone Joint Surg Am · 2019-01-01

该随机对照试验纳入200例初次全髋关节置换术患者,比较4种口服氨甲环酸方案对总失血量的影响。结果显示术后多次口服氨甲环酸较单次术前口服进一步减少失血,术前1剂加术后3剂方案失血量最低。各组血栓栓塞并发症和输血率无差异。

要点

  • B、C、D组总失血量均显著低于A组单次术前2.0g口服方案。
  • C组与D组失血量及血红蛋白下降无差异,D组为术前1剂加术后3剂。
  • 各组血栓栓塞并发症与输血率无差异。

核心结论

  • 与单次术前口服氨甲环酸相比,术后多次口服氨甲环酸进一步减少全髋关节置换术失血。
  • 术前1剂加术后3剂口服氨甲环酸方案在初次全髋关节置换术中产生最大有效失血量减少。

研究设计与样本

  • A组术前2小时口服2.0g氨甲环酸单次;B组同术前剂量加术后3小时口服1.0g;C组同术前剂量加术后3小时和9小时各口服1.0g;D组同术前剂量加术后3小时、9小时和15小时各口服1.0g。
  • 所有患者均接受1.0g局部氨甲环酸。

主要发现

  • 平均总失血量B组792.2±293.0 mL、C组630.8±229.9 mL、D组553.0±186.1 mL,均显著低于A组983.6±286.7 mL(p < 0.001)。
  • C组和D组血红蛋白平均下降幅度低于A组和B组。
  • C组与D组之间失血量和血红蛋白下降无差异。
  • 各组血栓栓塞并发症和输血率无差异。

关键数值与推荐

  • 主要结局为总失血量;次要结局包括血红蛋白下降、输血率、血栓栓塞并发症和不良事件。
  • 证据等级为治疗性I级。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Previous studies have confirmed that, compared with intravenous and intra-articular formulations, oral tranexamic acid (TXA) provides equivalent reduction in blood loss, at a substantially reduced cost and greater ease of administration. However, the optimal oral dosage regimen to achieve maximum blood-loss reduction remains unclear. The aim of this study was to assess the efficacy of a regimen of multiple doses of oral TXA on blood loss in primary total hip arthroplasty. METHODS: In this randomized controlled trial, 200 patients were randomized to 1 of 4 interventions. Group A received a single dose of 2.0 g of TXA orally at 2 hours preoperatively. In addition to this same preoperative dose, Group B received 1.0 g of TXA orally at 3 hours postoperatively, Group C received 1.0 g of TXA orally at 3 and 9 hours postoperatively, and Group D received 1.0 g of TXA orally at 3, 9, and 15 hours postoperatively. All patients received a 1.0-g topical dose of TXA. The primary outcome was total blood loss. Secondary outcomes included hemoglobin reduction, transfusion rate, thromboembolic complications, and adverse events. RESULTS: The mean total blood loss (and standard deviation) was significantly less in Groups B, C, and D (792.2 ± 293.0, 630.8 ± 229.9, and 553.0 ± 186.1 mL, respectively) than in Group A (983.6 ± 286.7 mL) (p < 0.001). Moreover, Groups C and D had a lower mean reduction in hemoglobin than did Groups A and B. However, no differences were identified between Groups C and D for blood loss and hemoglobin reduction. Additionally, no differences were observed among the groups regarding thromboembolic complications and transfusions. CONCLUSIONS: The multiple postoperative doses of oral TXA further reduced blood loss compared with a single preoperative bolus. The regimen of a preoperative dose and 3 postoperative doses of oral TXA produced maximum effective reduction of blood loss in total hip arthroplasty. LEVEL OF EVIDENCE: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Wang D, Wang HY, Luo ZY, et al. Finding the Optimal Regimen for Oral Tranexamic Acid Administration in Primary Total Hip Arthroplasty: A Randomized Controlled Trial. J Bone Joint Surg Am. 2019. PMID: 30845038. doi:10.2106/JBJS.18.00128

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。